The contrary view might be that she is risking a lot moving from...

The contrary view might be that she is risking a lot moving from a secure position with Pfizer to the unknown. She cannot even be sure that she will be retained long term by Impedimed. Whether it is opportunistic, or whether she is seeking a challenge.
To try to plan for growth at Impedimed without letting costs explode is going to be a huge challenge.
However, to be honest, if I could do the last six months again, I would have sold at 18¢ , and put the principal plus gains into one of several opportunities that I saw then. It is very uncomfortable to have to wait and hope now - but so would it have been under the old team, as the momentum would have faded anyway.